期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Re., ＇Use of androgen deprivation therapy in prostate ：ancer： indications and prevalence＇ by Connolly et al. 被引量：2

Re., ＇Use of androgen deprivation therapy in prostate ：ancer： indications and prevalence＇ by Connolly et al.
下载PDF
导出
摘要 Dear Editor, With regard to the article ＇Use of androgen deprivation therapy in prostate cancer： indications and prevalence＇1 which was published in Asian JAndro12012; 14： 177-86, we would like to highlight a number of factual inaccuracies and areas that warrant further discussion. Dear Editor, With regard to the article ＇Use of androgen deprivation therapy in prostate cancer： indications and prevalence＇1 which was published in Asian JAndro12012; 14： 177-86, we would like to highlight a number of factual inaccuracies and areas that warrant further discussion.
作者 Bo-Eric Persson
机构地区 Ferring Pharmaceuticals
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2012年第5期795-795,共1页 亚洲男性学杂志（英文版）
分类号 Q78 [生物学—分子生物学] Q579.11 [生物学—生物化学]
  • 相关文献

参考文献1

二级参考文献77

  • 1Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29: 2040-5.
  • 2Bolla M, van Poppel H, Tombal B. 10-year results of adjuvant radiotherapy after radical prostatectomy in pT3NO prostate cancer (EORTC 22991) (abstract). Int J Radiat Biol Phys 2010; 78: s29.
  • 3Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G etal. Adjuvant radiotherapy for pathological T3NOMO prostate cancer significantly reduces risk of metastases and improves survivah Iong-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62.
  • 4Whittington R, Broderick GA, Arger P, Malkowicz SB, Epperson RD et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44:1107-10.
  • 5Zelefsky M J, Leibel SA, Burman CM, Kutcher G J, Harrison A et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755-61.
  • 6D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A etal. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with crinicarly localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-7.
  • 7Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP etal. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-18.
  • 8Lawton CA, DeSilvio M, Roach M 3rd, U hl V, Kitsch R etal. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646--55.
  • 9Crook J, Ludgate C, Malone S, Lim J, Perry Get al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant a ndrogen deprivation before standard-dose radiotherapy for clinicatly localized prostate cancer.Int J Radiat Oncol Biol Phys 2004; 60: 15-23.
  • 10Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.

共引文献7

同被引文献10

引证文献2

二级引证文献6

Asian Journal of Andrology
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部